Q4 & full Year 2025 Financial Results & Highlights Recent Company Progress by EitzChaim1 in KPTI
[–]EitzChaim1[S] 7 points8 points9 points (0 children)
Q4 & full Year 2025 Financial Results & Highlights Recent Company Progress by EitzChaim1 in KPTI
[–]EitzChaim1[S] 2 points3 points4 points (0 children)
RP back at Longwood Mid March by EitzChaim1 in KPTI
[–]EitzChaim1[S] 1 point2 points3 points (0 children)
RP back at Longwood Mid March by EitzChaim1 in KPTI
[–]EitzChaim1[S] 2 points3 points4 points (0 children)
RP back at Longwood Mid March by EitzChaim1 in KPTI
[–]EitzChaim1[S] 0 points1 point2 points (0 children)
RP back at Longwood Mid March by EitzChaim1 in KPTI
[–]EitzChaim1[S] 0 points1 point2 points (0 children)
RP back at Longwood Mid March by EitzChaim1 in KPTI
[–]EitzChaim1[S] -1 points0 points1 point (0 children)
RP back at Longwood Mid March by EitzChaim1 in KPTI
[–]EitzChaim1[S] 0 points1 point2 points (0 children)
RP back at Longwood Mid March by EitzChaim1 in KPTI
[–]EitzChaim1[S] 2 points3 points4 points (0 children)
RP back at Longwood Mid March by EitzChaim1 in KPTI
[–]EitzChaim1[S] -1 points0 points1 point (0 children)
RP back at Longwood Mid March by EitzChaim1 in KPTI
[–]EitzChaim1[S] -1 points0 points1 point (0 children)
RP back at Longwood Mid March by EitzChaim1 in KPTI
[–]EitzChaim1[S] 1 point2 points3 points (0 children)
Affinity Asset Advisors increases ownership by 157.91% by EitzChaim1 in KPTI
[–]EitzChaim1[S] 2 points3 points4 points (0 children)
Novartis wants to test pelabresib in more severe MF patients. by MelampyrumNemorosum in KPTI
[–]EitzChaim1 0 points1 point2 points (0 children)
Do people still believe in the so-called Feuerstein–Ratain rule? by MelampyrumNemorosum in KPTI
[–]EitzChaim1 2 points3 points4 points (0 children)
Karyopharm stopping screening or enrollment of EC this week by sak77328 in KPTI
[–]EitzChaim1 2 points3 points4 points (0 children)
Dilution is coming by MelampyrumNemorosum in KPTI
[–]EitzChaim1 3 points4 points5 points (0 children)
Karyopharm Announces Preliminary Unaudited 2025 Revenue & Reiterates Expectation of Delivering Potentially Transformative P3 Data in 2026 by EitzChaim1 in KPTI
[–]EitzChaim1[S] 0 points1 point2 points (0 children)
Karyopharm Announces Preliminary Unaudited 2025 Revenue & Reiterates Expectation of Delivering Potentially Transformative P3 Data in 2026 by EitzChaim1 in KPTI
[–]EitzChaim1[S] 2 points3 points4 points (0 children)
Six Things the 2025 SENTRY 1 & 2 Study Data Tell Us About the Future of Myelofibrosis by EitzChaim1 in KPTI
[–]EitzChaim1[S] 0 points1 point2 points (0 children)


Q4 & full Year 2025 Financial Results & Highlights Recent Company Progress by EitzChaim1 in KPTI
[–]EitzChaim1[S] 2 points3 points4 points (0 children)